Treatment News : Stribild Is Comparable to Other Single-Tablet Combo Therapies

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 20, 2012

Stribild Is Comparable to Other Single-Tablet Combo Therapies

Single-tablet HIV regimen Stribild—the new quad combo pill from Gilead Sciences—is non-inferior to both Atripla and to ritonavir-boosted atazanavir plus Truvada in first-time treatment takers, the BusinessWire reports. Jürgen Rockstroh, MD, a professor of medicine at the University of Bonn, Germany, made an oral presentation of two 96-week Phase III studies comparing these drug regimens at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) in Glasgow. Approved by the U.S. Food and Drug Administration in August 2012 for treatment-naive people with HIV, Stribild is comprised of elvitegravir, cobicistat, emtricitabine and tenofovir.

One study compared 348 treatment-naive patients taking Stribild with 352 taking Atripla (efavirenz, emtricitabine, tenofovir). Findings showed that, after 96 weeks of treatment, 293 of those on Stribild, or 84 percent, had an undetectable viral load, compared with 287, Atripla patients, or 82 percent. Meanwhile, the study comparing 353 Stribild patients with 355 taking the ritonavir-boosted atazanavir plus Truvada (emtricitabine and tenofovir) regimen saw that 293, or 83 percent, of those taking Stribild and 292, or  82 percent, of those taking Truvada were undetectable at 96 weeks. For all three therapies, a similar percentage of participants stopped the regimen due to adverse events: Five percent of Stribild patients in both studies, 7 percent of Atripla patients, and 6 percent for those on the Truvada regimen.

To read the BusinessWire report, click here.

To read Gilead’s release, click here.

Search: HIV, stribild, combo, quad, Gilead Sciences, Atripla, ritonavir-boosted atazanavir, Truvada, treatment naive, BusinessWire, Jürgen Rockstroh, University of Bonn, Phase III, 11th International Congress on Drug Therapy in HIV Infection, Glasgow, FDA, efavirenz, emtricitabine, tenofovir, undetectable, viral load.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.